SHR-2554
- Generic Name
- SHR-2554
SHR-1701 Combined with SHR2554 and BP102 for MCRC
- Conditions
- Colorectal Cancer Metastatic
- Interventions
- First Posted Date
- 2024-11-07
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 20
- Registration Number
- NCT06679673
- Locations
- 🇨🇳
Department of Colorectal Surgery Fudan University Shanghai Caner Center, Shanghai, Shanghai, China
Exploratory Clinical Study of SHR-0302 and SHR-2554 in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma
- Conditions
- Relapsed/Refractory Peripheral T Cell Lymphoma
- Interventions
- First Posted Date
- 2024-07-25
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 25
- Registration Number
- NCT06519526
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
A Phase II Study of SHR2554 in Patients With Relapsed or Refractory Follicular Lymphoma
- First Posted Date
- 2024-04-16
- Last Posted Date
- 2024-04-16
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 105
- Registration Number
- NCT06368167
- Locations
- 🇨🇳
Peking University Cancer Hospital, Beijing, Beijing, China
Pharmacokinetic Test of High-fat Diet After Oral Administration of SHR2554 in Healthy Subjects
- First Posted Date
- 2022-10-24
- Last Posted Date
- 2022-12-19
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT05592262
- Locations
- 🇨🇳
Zhongshan Hospital Affiliated to Fudan University, Shanghai, Shanghai, China
A Umbrella Study in R/R PTCL Guided by Molecular Subtypes
- Conditions
- Peripheral T Cell Lymphoma
- Interventions
- First Posted Date
- 2022-09-29
- Last Posted Date
- 2022-11-09
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 116
- Registration Number
- NCT05559008
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China
Molecularly Targeted Umbrella Study in Luminal Advanced Breast Cancer
- Conditions
- Breast CancerMetastatic Cancer
- Interventions
- First Posted Date
- 2020-04-21
- Last Posted Date
- 2022-07-26
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 319
- Registration Number
- NCT04355858
- Locations
- 🇨🇳
Cancer Hospital Affiliated to Fudan University, Shanghai, Shanghai, China
A Food Effect Study of SHR2554 on Healthy Chinese Male Adult Subjects
- First Posted Date
- 2020-04-06
- Last Posted Date
- 2020-04-06
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT04335266
- Locations
- 🇨🇳
Henan Cancer Hospital, Henan, China
A Study of SHR2554 Alone or in Combination With SHR3680 in the Treatment of mCRPC
- Conditions
- Castration-resistant Prostate CancerProstate Cancer
- Interventions
- First Posted Date
- 2018-11-15
- Last Posted Date
- 2021-02-05
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 9
- Registration Number
- NCT03741712
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
A Phase 1 Study of SHR2554 in Subjects With Relapsed or Refractory Mature Lymphoid Neoplasms
- Conditions
- Relapsed or Refractory Mature Lymphoid Neoplasms
- Interventions
- First Posted Date
- 2018-07-27
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 272
- Registration Number
- NCT03603951
- Locations
- 🇨🇳
Beijing Cancer Hospital, Peking University, Beijing, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.